|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This site is dedicated to Cindi McCain & Lou Grubb: Friends & Stroke Survivors....(ALLOW 1 MINUTE TO LOAD)....We search 100's of internet sites for daily news: New York Times, Washington Post, LA Times, Chicago Tribune, Harvard, Yale, UCLA, CNN, FOX, CBS, NBC, ABC, BBC, Journal of American Medical Assoc., New England Journal of Medicine, Mayo Clinic, Johns Hopkins Medicine, Cleveland Clinic, Memorial Sloan- Kettering, Reuters & 100's more...(WE DO NOT ACCEPT ADVERTISING) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
SundayFDA Approves Atacand® (Candesartan Cilexetil) for the Treatment of Heart Failure
[LINK]AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) ATACAND® (candesartan cilexetil) for the treatment of heart failure (New York Heart Association Class II-IV and ejection fraction less than or equal to 40 percent) to reduce the risk of death from cardiovascular causes and reduce hospitalisations from heart failure. ATACAND is the first ARB in the US to receive an indication for reducing both cardiovascular mortality and hospitalisations for heart failure.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||